(19)
(11) EP 1 934 246 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.02.2012 Bulletin 2012/06

(45) Mention of the grant of the patent:
24.08.2011 Bulletin 2011/34

(21) Application number: 06792355.7

(22) Date of filing: 03.10.2006
(51) International Patent Classification (IPC): 
C07K 14/435(2006.01)
C07K 19/00(2006.01)
 C12N 9/64(2006.01)
A61K 39/00(2006.01)
(86) International application number:
PCT/EP2006/009536
(87) International publication number:
WO 2007/042169 (19.04.2007 Gazette 2007/16)

(54)

MATRIX METALLOPROTEINASE 11 VACCINE

MATRIXMETALLOPROTEINASE-11-IMPFSTOFF

VACCIN DE METALLOPROTEINASE 11 MATRICIELLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 07.10.2005 US 724498 P

(43) Date of publication of application:
25.06.2008 Bulletin 2008/26

(73) Proprietor: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.
00189 Roma (IT)

(72) Inventors:
  • AURISICCHIO, Luigi
    I-00040 Pomezia (Rome) (IT)
  • LA MONICA, Nicola
    I-00040 Pomezia (Rome) (IT)
  • CILIBERTO, Gennaro
    I-00040 Pomezia (Rome) (IT)
  • LAZZARO, Domenico
    I-00040 Pomezia (Rome) (IT)
  • MORI, Federica
    I-00040 Pomezia (Rome) (IT)
  • PERUZZI, Daniela
    I-00040 Pomezia (Rome) (IT)

(74) Representative: Horgan, James Michael Frederic et al
Merck & Co., Inc. European Patent Department Hertford Road
Hoddesdon EN11 9BU
Hoddesdon EN11 9BU (GB)


(56) References cited: : 
WO-A2-2004/052301
 WO-A2-2005/077977
   
  • WU E ET AL: "Stromelysin-3 suppresses tumor cell apoptosis in a murine model." JOURNAL OF CELLULAR BIOCHEMISTRY. 2001, vol. 82, no. 4, 2001, pages 549-555, XP002410649 ISSN: 0730-2312
  • NOEL A ET AL: "Demonstration in vivo that stromelysin-3 functions through its proteolytic activity" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 19, 2000, pages 1605-1612, XP002982814 ISSN: 0950-9232 cited in the application
  • FROMIGUÉ OLIVIA ET AL: "Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 1 SEP 2003, vol. 106, no. 3, 1 September 2003 (2003-09-01), pages 355-363, XP002410712 ISSN: 0020-7136
  • DAMJANOVSKI S ET AL: "Overexpression of matrix metalloproteinases leads to lethality in transgenic Xenopus laevis: implications for tissue-dependent functions of matrix metalloproteinases during late embryonic development." DEVELOPMENTAL DYNAMICS : AN OFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION OF ANATOMISTS. MAY 2001, vol. 221, no. 1, May 2001 (2001-05), pages 37-47, XP002410650 ISSN: 1058-8388
  • FU LIEZHEN ET AL: "A causative role of stromelysin-3 in extracellular matrix remodeling and epithelial apoptosis during intestinal metamorphosis in Xenopus laevis." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 29 JUL 2005, vol. 280, no. 30, 29 July 2005 (2005-07-29), pages 27856-27865, XP002410651 ISSN: 0021-9258
  • BASSET P ET AL: "A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas." NATURE. 1990 DEC 20-27, vol. 348, no. 6303, 20 December 1990 (1990-12-20), pages 699-704, XP002410652 ISSN: 0028-0836
  • ANDARAWEWA KUMARI L ET AL: "Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front." CANCER RESEARCH. 1 DEC 2005, vol. 65, no. 23, 1 December 2005 (2005-12-01), pages 10862-10871, XP002410653 ISSN: 0008-5472
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).